Reaction mass of dodecyl acrylate and tridecyl acrylate

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1964

Report date:

1964

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-Propenoic acid, C12-14-alkyl esters

EC Number:

282-516-8

EC Name:

2-Propenoic acid, C12-14-alkyl esters

Cas Number:

84238-60-8

Molecular formula:

Unspecified

IUPAC Name:

84238-60-8

Test animals

Species:

rat

Strain:

not specified

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: aqueous emulsion (30%) with traganth

Doses:

0.2, 1.6, 3.2, and 6.4 mL/kg bw (corresponding to 174, 1392, 2784, and 5568 mg/kg bw)

No. of animals per sex per dose:

5

Control animals:

not specified

Details on study design:

The study was conducted according to an internal BASF method which in principle is comparable to the methods described in OECD Guideline 401. Several groups of 5 rats per sex and dose were treated simultaneously by gavage with preparations of the test substance in aqueous emulsion with traganth.
Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form. Upon completion of the study, all animals were sacrificed and submitted to gross-pathological examination.

Statistics:

no

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD0

Effect level:

> 5 570 mg/kg bw

Based on:

test mat.

Remarks on result:

not determinable due to absence of adverse toxic effects

Mortality:

No mortality

Clinical signs:

The animals of the highest dose group showed slight apathy and piloerection during the first 24 hours. Among the animals of the next two dose groups (2784 and 1392 mg/kg bw) slight apathy was also observed. No other clinical signs were recorded. All symptoms disappeared within the first day of the experiment.

Body weight:

Mean body weight at test start: 243 g (male); 173 g (female)

Gross pathology:

No macroscopic pathologic abnormalities were noted in the surviving animals examined at the end of the observation period.

Any other information on results incl. tables

Mortality:
----------
 Dose          No. of          Cumulative mortality after
[mg/kg bw]   animals       1 h     24 h      48 h     7 d
-----------------------------------------------------------
 5568          10         0/10     0/10      0/10     0/10
 2784          10         0/10     0/10      0/10     0/10
 1392          10         0/10     0/10      0/10     0/10
  174           10         0/10     0/10      0/10     0/10
----------------------------------------------------------- 

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

Based on the results, the oral LD50 of laurylacrylate is higher than 5570 mg/kg bw in rats.

Executive summary:

The study was conducted according to an internal BASF method which in  principle is comparable to the methods described in OECD Guideline 401. Several groups of 5 rats per sex and dose were treated simultaneously by  gavage with preparations of the test substance in aqueous emulsion with traganth. 4 doses were tested : 174, 1392, 2784 and 5568 mg/kg bw

Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. Upon completion of the study, all animals were sacrificed and submitted to gross-pathological examination.

No mortality was observed in the study. The animals of the highest dose group showed slight apathy and  piloerection during the first 24 hours. Among the animals of the next two dose groups (2784 and 1392 mg/kg bw) slight apathy was also observed. No other clinical signs were recorded. All symptoms disappeared within the first day of the experiment. No macroscopic pathologic abnormalities were noted in the animals examined at the end of the observation period.

Based on the results, the oral LD50 of laurylacrylate is higher than 5570 mg/kg bw in rats.